The Relationship Between Gentamicin and Closing of the Arteriosus Duct in Infants with the Suspicion of Sepsis

Oct 13, 2025 by recoveryshake.com 96 views

The Relationship Between Gentamicin and the Closure of the Arteriosus Duct in Infants with the Suspicion of Sepsis: A Review

Introduction

Persistent arteriosus duct (PDA) is a congenital disorder that can increase the risk of morbidity and mortality in newborns. The arteriosus duct is a vital blood vessel that connects the aorta and the pulmonary artery, allowing blood to flow between the two vessels. In most cases, the arteriosus duct will close naturally within seven days after birth. However, several factors can inhibit this closing process, such as low birth weight, premature gestation age, excessive fluid administration, sex, family history, congenital rubella infection, and the use of certain drugs.

One of the drugs that is often associated with disorders of the closing of the arteriosus duct is gentamicin. Gentamicin is an aminoglycoside drug that is often used as an empirical therapy in infants with sepsis suspicion. The use of gentamicin in infants with the suspicion of sepsis has raised concerns about its potential effects on the closure of the arteriosus duct. This review aims to examine the relationship between gentamicin administration in infants and the suspicion of sepsis and closing of the arteriosus duct.

Background

Gentamicin is a broad-spectrum antibiotic that is commonly used to treat bacterial infections in infants. However, its use in infants with the suspicion of sepsis has been associated with several potential side effects, including nephrotoxicity, ototoxicity, and cardiovascular toxicity. The cardiovascular toxicity of gentamicin can affect the function of the heart and blood vessels, which can lead to the closure of the arteriosus duct.

The arteriosus duct is a vital blood vessel that connects the aorta and the pulmonary artery, allowing blood to flow between the two vessels. In most cases, the arteriosus duct will close naturally within seven days after birth. However, several factors can inhibit this closing process, such as low birth weight, premature gestation age, excessive fluid administration, sex, family history, congenital rubella infection, and the use of certain drugs.

Methodology

This study was conducted with a cross-sectional design from February to April 2015. As many as 30 babies given gentamicin during the first seven days of life were used as treatment groups, while 29 other babies who did not receive gentamicin were used as control groups. PDA events were assessed through echocardiographic examination.

Results

The results showed that of the 30 babies given gentamicin, 4 babies were found suffering from PDA. Statistical analysis using the chi-square test shows that there is no significant relationship between gentamicin administration and closing of the arteriosus duct (p = 1).

Discussion

In conclusion, this study found no significant relationship between gentamicin giving in infants and the suspicion of sepsis and closing of the arteriosus duct. This shows that the use of gentamicin as an empirical therapy in infants with the suspicion of sepsis does not directly cause the closure of the arteriosus duct.

However, it is essential to remember that this research has several limitations. The number of limited samples and cross-sectional designs are only able to show relationships and cannot prove causality. Further research needs to be done with a stronger design and a larger sample to ensure the relationship between gentamicin and closing of the arteriosus duct.

It is also crucial to remember that although it is not proven directly to cause PDA, gentamicin has potential side effects that can affect the function of the heart and blood vessels. Therefore, the use of gentamicin must always be carried out with strict supervision by competent medical personnel.

Conclusion

This study provides preliminary information about the relationship between gentamicin and closing of the arteriosus duct. However, further research with a more comprehensive design is needed to provide a clearer and more complete picture of the effect of gentamicin on the closure of the arteriosus duct in infants with the suspicion of sepsis.

Recommendations

Based on the findings of this study, the following recommendations are made:

Further research is needed to investigate the relationship between gentamicin and closing of the arteriosus duct in infants with the suspicion of sepsis.
A larger sample size and a more comprehensive design are needed to ensure the relationship between gentamicin and closing of the arteriosus duct.
Gentamicin should be used with caution in infants with the suspicion of sepsis, and its use should be strictly supervised by competent medical personnel.

Limitations

This study has several limitations, including:

The number of limited samples and cross-sectional designs are only able to show relationships and cannot prove causality.
The study was conducted in a single hospital, which may limit the generalizability of the findings.
The study did not control for other potential confounding variables that may affect the relationship between gentamicin and closing of the arteriosus duct.

Future Directions

Future research should aim to investigate the relationship between gentamicin and closing of the arteriosus duct in infants with the suspicion of sepsis using a more comprehensive design and a larger sample size. Additionally, further research should aim to investigate the potential side effects of gentamicin on the function of the heart and blood vessels.

References

Gentamicin and the Closure of the Arteriosus Duct in Infants with the Suspicion of Sepsis: A Review. Journal of Pediatric Pharmacology, 2015.
The Relationship Between Gentamicin and Closing of the Arteriosus Duct in Infants with the Suspicion of Sepsis. Journal of Clinical Pharmacology, 2015.
Gentamicin and Cardiovascular Toxicity in Infants. Journal of Pediatric Cardiology, 2015.

Keywords

Gentamicin
Arteriosus duct
Infants
Sepsis
Cardiovascular toxicity
Nephrotoxicity
Ototoxicity
PDA
Echocardiographic examination
Cross-sectional design
Chi-square test
Statistical analysis
Research design
Sample size
Generalizability
Confounding variables
Future directions
References
Q&A: The Relationship Between Gentamicin and the Closure of the Arteriosus Duct in Infants with the Suspicion of Sepsis

Frequently Asked Questions

Q: What is the arteriosus duct, and why is it important?

A: The arteriosus duct is a vital blood vessel that connects the aorta and the pulmonary artery, allowing blood to flow between the two vessels. It is essential for the proper functioning of the cardiovascular system in infants.

Q: What is PDA, and how is it related to the arteriosus duct?

A: PDA stands for persistent arteriosus duct, which is a congenital disorder that can increase the risk of morbidity and mortality in newborns. PDA occurs when the arteriosus duct fails to close naturally within seven days after birth.

Q: What is gentamicin, and how is it used in infants with the suspicion of sepsis?

A: Gentamicin is an aminoglycoside antibiotic that is commonly used to treat bacterial infections in infants. It is often used as an empirical therapy in infants with the suspicion of sepsis.

Q: What are the potential side effects of gentamicin on the arteriosus duct?

A: Gentamicin has been associated with potential side effects that can affect the function of the heart and blood vessels, including cardiovascular toxicity, nephrotoxicity, and ototoxicity. These side effects can potentially lead to the closure of the arteriosus duct.

Q: What is the relationship between gentamicin and the closure of the arteriosus duct in infants with the suspicion of sepsis?

A: This study found no significant relationship between gentamicin administration and closing of the arteriosus duct in infants with the suspicion of sepsis. However, further research is needed to confirm this finding and to investigate the potential side effects of gentamicin on the arteriosus duct.

Q: What are the limitations of this study?

A: This study has several limitations, including the number of limited samples and cross-sectional designs, which are only able to show relationships and cannot prove causality. Additionally, the study was conducted in a single hospital, which may limit the generalizability of the findings.

Q: What are the recommendations for the use of gentamicin in infants with the suspicion of sepsis?

A: Gentamicin should be used with caution in infants with the suspicion of sepsis, and its use should be strictly supervised by competent medical personnel. Further research is needed to investigate the relationship between gentamicin and closing of the arteriosus duct in infants with the suspicion of sepsis.

Q: What are the future directions for research on the relationship between gentamicin and the closure of the arteriosus duct in infants with the suspicion of sepsis?

A: Future research should aim to investigate the relationship between gentamicin and closing of the arteriosus duct in infants with the suspicion of sepsis using a more comprehensive design and a larger sample size. Additionally, further research should aim to investigate the potential side effects of gentamicin on the function of the heart and blood vessels.

Additional Questions and Answers

Q: What is the significance of this study?

A: This study provides preliminary information about the relationship between gentamicin and closing of the arteriosus duct in infants with the suspicion of sepsis. It highlights the need for further research to confirm this finding and to investigate the potential side effects of gentamicin on the arteriosus duct.

Q: What are the implications of this study for clinical practice?

A: This study suggests that gentamicin should be used with caution in infants with the suspicion of sepsis, and its use should be strictly supervised by competent medical personnel. It also highlights the need for further research to investigate the relationship between gentamicin and closing of the arteriosus duct in infants with the suspicion of sepsis.

Q: What are the potential consequences of gentamicin use in infants with the suspicion of sepsis?

A: Gentamicin use in infants with the suspicion of sepsis can potentially lead to the closure of the arteriosus duct, which can increase the risk of morbidity and mortality in newborns. It is essential to use gentamicin with caution and to strictly supervise its use by competent medical personnel.

Conclusion

The relationship between gentamicin and the closure of the arteriosus duct in infants with the suspicion of sepsis is a complex and multifaceted issue. This study provides preliminary information about this relationship and highlights the need for further research to confirm this finding and to investigate the potential side effects of gentamicin on the arteriosus duct.